news
METIS data at ASCO Annual Meeting
Data from our positive phase 3 METIS clinical trial were presented on June 3 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
learn moreNovocure reports Q3 financial results and announces the appointment of Christoph Brackmann as CFO, effective January 1, 2025. For more information, see our press releases: https://www.novocure.com/press-releases/
FDA approves Novocure’s treatment for metastatic non-small cell lung cancer (mNSCLC) for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with mNSCLC who progressed on or after a platinum-based regimen: https://www.novocure.com/fda-approves-novocures-optune-lua-for-the-treatment-of-metastatic-non-small-cell-lung-cancer/
Novocure will participate in the 2024 Wells Fargo Healthcare Conference on September 4. William Doyle, our Executive Chairman, will take part in a fireside chat at 4:30 p.m. EST, as well as one-on-one meetings with investors. Listen live on Sep 4 here: https://www.novocure.com/investor-relations/
This #WorldLungCancerDay, we thank the doctors, nurses, caregivers, patient organizations and all who support patients facing this difficult disease. #lungcancer
We reported financial results for the quarter ended June 30, 2024, including quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, up 11% compared to the same period in 2023. https://www.novocure.com/novocure-reports-second-quarter-2024-financial-results/
#earnings #NVCR
Today marks the 6th annual #GBMDay, when patients, caregivers, and advocates come together to support those living with #glioblastoma, remember those we have lost, and reaffirm our commitment to developing innovative treatments and, ultimately, a cure for this disease.